Dare Bioscience, Inc. (DARE) - Form 8-K Summary
Business Context and Reporting Period
Dare Bioscience, Inc., a Delaware corporation, filed this Current Report on Form 8-K on May 13, 2025. The filing serves to announce the Company's financial results for the quarter ended March 31, 2025. The Company's common stock trades on the Nasdaq Capital Market under the symbol "DARE."
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were issued in a press release (Exhibit 99.1) but does not reproduce the financial data within the 8-K text itself.
Material Changes
The filing text does not provide details on material changes versus the prior comparable period. Investors must refer to the referenced press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in this excerpt.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 13, 2025) for actual Q1 2025 financial figures.
- Verify the Company's cash position and burn rate in the full press release to assess liquidity runway.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm if the Company provided updated full-year 2025 guidance in the accompanying materials.